Syneos Health Collaborates with Microsoft to Accelerate AI Across the Clinical to Commercial Continuum
March 20 2023 - 6:45AM
Syneos Health® (Nasdaq:SYNH), a leading fully integrated
biopharmaceutical solutions organization, today announced a
strategic multi-year agreement with Microsoft. Utilizing Microsoft
Azure services, Syneos Health has developed an advanced analytics
platform that enables agile deployment of machine learning (ML)
supporting the analysis, design and execution of clinical trials
and commercial programs worldwide.
The multi-year agreement includes collaboration with Microsoft
Research and leverages developments from OpenAI. Through this
collaboration, Syneos Health will deliver technology and data
solutions with Microsoft that accelerate clinical development and
elevate commercial performance for biopharma customers.
Based on this AI-enabled platform, Syneos Health is able to
process and analyze data to fast-track timelines, optimize resource
allocation and unlock clinical trial efficiencies. These
capabilities will allow for superior site selection and reduced
enrollment timelines to bring new treatments to patients
faster.
“Microsoft is the ideal technology partner for Syneos Health,”
said Michelle Keefe, CEO, Syneos Health. “Their clear industry
leadership in AI and their pragmatic approach to improving
healthcare outcomes for patients, science and industry is
completely aligned with our value proposition. We look forward to a
strong relationship for years to come – one that drives innovative
solutions to accelerate our customers’ success.”
“We are pleased to work with Syneos Health to bring our
expertise in AI together with their solutions to help make a
meaningful difference in the lives of patients,” said Patty
Obermaier, Vice President, U.S. Health and Life Sciences,
Microsoft. “Syneos Health’s integration of Azure Synapse Analytics,
Azure Data Factory, Azure SQL Database, and other Azure services,
allows them to develop a platform that empowers biopharma customers
to deliver therapies to patients faster.”
About Syneos Health
Syneos Health® (Nasdaq:SYNH) is a leading fully integrated
biopharmaceutical solutions organization built to accelerate
customer success. We translate unique clinical, medical affairs and
commercial insights into outcomes to address modern market
realities.
We bring together a talented team of professionals, who work
across more than 110 countries, with a deep understanding of
patient and physician behaviors and market dynamics. Together
we share insights, use the latest technologies and apply advanced
business practices to speed our customers’ delivery of important
therapies to patients.
Syneos Health supports a diverse, equitable and inclusive
culture that cares for colleagues, customers, patients, communities
and the environment.
To learn more about how we are Shortening the distance
from lab to life®, visit syneoshealth.com or subscribe to
our podcast.
Syneos Health Contacts: |
Investor
RelationsRonnie SpeightSenior Vice President, Investor Relations+1
919 745 2745Investor.Relations@syneoshealth.com |
|
Press/MediaGary GatyasExecutive Director, External Communications+1
908 763 3428gary.gatyas@syneoshealth.com |
Syneos Health (NASDAQ:SYNH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Syneos Health (NASDAQ:SYNH)
Historical Stock Chart
From Jul 2023 to Jul 2024